hims glp-1 & Hers set for Super Bowl ad debut highlighting weight loss drugs Earnings from Eli Lilly, Novo
Description
Can you use GLP-1 medications if you have Crohn's disease
Novo Nordisk announced that its rebranded and reformulated oral GLP-1 medication, formerly known as Rybelsus, is now available in the U.S
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
Learn more about these findings:
